Edrecolomab ELISA Kit

Edrecolomab ELISA Kit is a quantitative ELISA kit for detection of Edrecolomab.

Edrecolomab, also known as MAb17-1A, is a mouse-derived IgG2a monoclonal antibody targeted at the cell-surface glycoprotein EpCAM (17-1A). This drug was developed by Centocor in an attempt to prevent colorectal cancer and adenocarcinoma. Edrecolomab has been investigated in the clinical trials for the treatment of colon cancer. Edrecolomab was licensed as an adjuvant therapy for postoperative colorectal cancer by German authorities with the trade name Panorex in 1995. However, in 2004, researchers applied edrecolomab to the study of postoperative adjuvant therapy in patients with colorectal cancer. The results showed that edrecolomab adjuvant therapy can help Dukes'CCRC patients to restore the lack of immune response in the body, but the randomized trials of clinical efficacy were unsatisfactory. Then in 2005, Edrecolomab was studied in a phase 3 randomized trial of postoperative adjuvant therapy for colorectal cancer. However, the results showed that Edrecolomab did not improve overall survival or disease-free survival in patients with stage II colon cancer treated with postoperative adjuvant therapy. Subsequently, Edrecolomab in combination with fluorouracil (FU) was used to treat colorectal cancer in the III stage. However, the results showed that the addition of ED in the basic treatment of fluorouracil had no significant effect on OS. Edrecolomab also did not prolong patient survival in subsequent randomized trials. Although Edrecolomab has not shown very good results in previous studies of colorectal cancer, it is still a promising monoclonal antibody for the treatment of adenocarcinomas expressing EpCAM.

Target	Edrecolomab
Reactivity	Human
Tested Applications	ELISA
Recommended dilutions	Optimal dilutions/concentrations should be determined by the end user.
Storage	Shipped at 4 °C. Upon receipt, store the kit according to the storage instruction in the kit's manual.
Validity	The validity for this kit is 6 months.
Stability	The stability of the kit is determined by the rate of activity loss. The loss rate is less than 5% within the expiration date under appropriate storage conditions. To minimize performance fluctuations, operation procedures and lab conditions should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same user throughout.
Test Range	0.31 μg/ml - 5 μg/ml
Standard Form	Lyophilized
Detection Method	Colorimetric
Assay Type	Competitive
Assay Data	Quantitative
Sample Type	Serum and plasma.
CAS Number	156586-89-9
Availability	Shipped within 10-20 working days.
Note	This product is for research use only. The range and sensitivity is subject to change. Please contact us for the latest product information. For accurate results, sample concentrations must be diluted to mid-range of the kit. If you require a specific range, please contact us in advance or write your request in your order comments. Please note that our ELISA and CLIA kits are optimised for detection of native samples, rather than recombinant proteins. We are unable to guarantee detection of recombinant proteins, as they may have different sequences or tertiary structures to the native protein.

Research Articles on Edrecolomab

Write a review

Your Name

Your Email Address

PMID

DOI

Your Review

Rating

Continue